Up­dat­ed: Roivant’s FcRn an­ti­body for au­toim­mune dis­ease shows ear­ly po­ten­tial in study with healthy sub­jects

Roivant Sci­ences’ Im­muno­vant has un­veiled bio­mark­er re­sults for its au­toim­mune dis­ease an­ti­body drug from a Phase I healthy sub­ject tri­al.

The sub­cu­ta­neous drug, dubbed IMVT …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER